{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:39Z","timestamp":1792782879300,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neutropenia and agranulocytosis (N&amp;A) are relatively rare, but potentially fatal adverse drug reactions (ADR). This study presents cases of N&amp;A related to one or more antipsychotic drugs (APDs) in psychiatric inpatients. Data on APD utilization and reports of N&amp;A caused by APDs were analyzed by using data from an observational pharmacovigilance program in German-speaking countries\u2014Arzneimittelsicherheit in der Psychiatrie (AMSP)\u2014from 1993 to 2016. 333,175 psychiatric inpatients were treated with APDs for schizophrenia and other indications during the observation period. A total of 124 cases of APD-induced N&amp;A were documented, 48 of which fulfilled the criteria for agranulocytosis, corresponding to a rate of 0.37, respectively, 0.14 in 1000 inpatients treated with APDs. Neutropenia was more often detected in women, whereas there was no difference regarding sex in cases of agranulocytosis. Clozapine had the highest relative risk for inducing N&amp;A and was imputed alone as a probable cause of N&amp;A in 60 cases (1.57\u2030 of all patients exposed). Perazine showed the second highest relative risk with 8 cases and an incidence 0.52\u2030, followed by quetiapine (15 cases resp. 0.23\u2030 of all patients exposed) and olanzapine (7 cases; 0.13\u2030 of all patients exposed). N&amp;A most often occurred during the first 3 months of treatment. Overall N&amp;A are severe and potentially fatal complications that can occur during treatment with APDs. The results from this study largely agree with the currently available literature, highlighting the positive effects of alertness and established appropriate monitoring.<\/jats:p>","DOI":"10.1007\/s00702-023-02589-7","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T13:12:20Z","timestamp":1674047540000},"page":"153-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-8533","authenticated-orcid":false,"given":"Catherine","family":"Glocker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-5664","authenticated-orcid":false,"given":"G.","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-7419","authenticated-orcid":false,"given":"J.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8859-6907","authenticated-orcid":false,"given":"S.","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"St\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sch\u00fcle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"issue":"2","key":"2589_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/00031305.1998.10480550","volume":"52","author":"A Agresti","year":"1998","unstructured":"Agresti A, Coull BA (1998) Approximate is better than \u201cExact\u201d for interval estimation of binomial proportions. Am Stat 52(2):119\u2013126. https:\/\/doi.org\/10.1080\/00031305.1998.10480550","journal-title":"Am Stat"},{"issue":"3","key":"2589_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/nejm199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis Incidence and risk factors in the United States. N Engl J Med 329(3):162\u2013167. https:\/\/doi.org\/10.1056\/nejm199307153290303","journal-title":"N Engl J Med"},{"issue":"9","key":"2589_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","volume":"146","author":"F Andersohn","year":"2007","unstructured":"Andersohn F, Konzen C, Garbe E (2007) Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146(9):657\u2013665. https:\/\/doi.org\/10.7326\/0003-4819-146-9-200705010-00009","journal-title":"Ann Intern Med"},{"issue":"1","key":"2589_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","volume":"15","author":"E Andr\u00e8s","year":"2008","unstructured":"Andr\u00e8s E, Maloisel F (2008) Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 15(1):15\u201321. https:\/\/doi.org\/10.1097\/MOH.0b013e3282f15fb9","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"2589_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2165\/00002512-200421070-00002","volume":"21","author":"E Andr\u00e8s","year":"2004","unstructured":"Andr\u00e8s E, Noel E, Kurtz JE, Henoun Loukili N, Kaltenbach G, Maloisel F (2004) Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients. Drugs Aging 21(7):427\u2013435. https:\/\/doi.org\/10.2165\/00002512-200421070-00002","journal-title":"Drugs Aging"},{"issue":"1","key":"2589_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08104.x","volume":"150","author":"E Andr\u00e8s","year":"2010","unstructured":"Andr\u00e8s E, Maloisel F, Zimmer J (2010) The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol 150(1):3\u20138. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08104.x","journal-title":"Br J Haematol"},{"issue":"5","key":"2589_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/qjmed\/hcw220","volume":"110","author":"E Andr\u00e8s","year":"2017","unstructured":"Andr\u00e8s E, Mourot-Cottet R, Maloisel F, S\u00e9verac F, Keller O, Vogel T, Tebacher M, Weber JC, Kaltenbach G, Gottenberg JE, Goichot B, Sibilia J, Korganow AS, Herbrecht R (2017) Idiosyncratic drug-induced neutropenia & agranulocytosis. QJM 110(5):299\u2013305. https:\/\/doi.org\/10.1093\/qjmed\/hcw220","journal-title":"QJM"},{"issue":"10","key":"2589_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.5694\/j.1326-5377.1998.tb141414.x","volume":"168","author":"DL Copolov","year":"1998","unstructured":"Copolov DL, Bell WR, Benson WJ, Keks NA, Strazzeri DC, Johnson GF (1998) Clozapine treatment in Australia: a review of haematological monitoring. Med J Aust 168(10):495\u2013497. https:\/\/doi.org\/10.5694\/j.1326-5377.1998.tb141414.x","journal-title":"Med J Aust"},{"issue":"2","key":"2589_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.21307\/immunohematology-2019-103","volume":"30","author":"BR Curtis","year":"2014","unstructured":"Curtis BR (2014) Drug-induced immune neutropenia\/agranulocytosis. Immunohematology 30(2):95\u2013101","journal-title":"Immunohematology"},{"issue":"1","key":"2589_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/asheducation-2017.1.187","volume":"2017","author":"BR Curtis","year":"2017","unstructured":"Curtis BR (2017) Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program 2017(1):187\u2013193. https:\/\/doi.org\/10.1182\/asheducation-2017.1.187","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2589_CR11","first-page":"328","volume":"170","author":"RB Dessau","year":"2008","unstructured":"Dessau RB, Pipper CB (2008) \u201cR\u201d\u2013project for statistical computing. Ugeskr Laeger 170(5):328\u2013330 (R--en programpakke til statistisk databehandling og grafik.)","journal-title":"Ugeskr Laeger"},{"issue":"8","key":"2589_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1358\/dot.2005.41.8.893629","volume":"41","author":"HS Duggal","year":"2005","unstructured":"Duggal HS, Singh I (2005) Psychotropic drug-induced neutropenia. Drugs Today (barc) 41(8):517\u2013526. https:\/\/doi.org\/10.1358\/dot.2005.41.8.893629","journal-title":"Drugs Today (barc)"},{"issue":"6","key":"2589_CR13","doi-asserted-by":"publisher","first-page":"e8505","DOI":"10.7759\/cureus.8505","volume":"12","author":"V Fryer","year":"2020","unstructured":"Fryer V, Billings J (2020) Low-dose quetiapine causing agranulocytosis and leucopenia in a patient with benign neutropenia: a case report. Cureus 12(6):e8505. https:\/\/doi.org\/10.7759\/cureus.8505","journal-title":"Cureus"},{"issue":"3","key":"2589_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1517\/14740338.6.3.323","volume":"6","author":"E Garbe","year":"2007","unstructured":"Garbe E (2007) Non-chemotherapy drug-induced agranulocytosis. Expert Opin Drug Saf 6(3):323\u2013335. https:\/\/doi.org\/10.1517\/14740338.6.3.323","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2589_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/jcp.0000000000000752","volume":"37","author":"C Glocker","year":"2017","unstructured":"Glocker C, Grohmann R, Schulz H (2017) Fatal agranulocytosis associated with quetiapine in monotherapy: a case report. J Clin Psychopharmacol 37(5):625\u2013627. https:\/\/doi.org\/10.1097\/jcp.0000000000000752","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl","key":"2589_CR16","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1007\/bf00442573","volume":"99","author":"R Grohmann","year":"1989","unstructured":"Grohmann R, Schmidt LG, Spiess-Kiefer C, R\u00fcther E (1989) Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMUP program. Psychopharmacology 99(Suppl):S109-112. https:\/\/doi.org\/10.1007\/bf00442573","journal-title":"Psychopharmacology"},{"issue":"Suppl 1","key":"2589_CR17","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1055\/s-2004-815505","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Engel RR, R\u00fcther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):S4-11. https:\/\/doi.org\/10.1055\/s-2004-815505","journal-title":"Pharmacopsychiatry"},{"issue":"40","key":"2589_CR18","first-page":"924","volume":"10","author":"J Hiob","year":"1955","unstructured":"Hiob J, Hippius H (1955) Agranulocytosis following administration of phenothiazine derivatives. Arztl Wochensch 10(40):924\u2013925 (Agranulocytose nach Behandlung mit Phenothiazinderivaten.)","journal-title":"Arztl Wochensch"},{"issue":"8","key":"2589_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archinte.165.8.869","volume":"165","author":"L Ib\u00e1\u00f1ez","year":"2005","unstructured":"Ib\u00e1\u00f1ez L, Vidal X, Ballar\u00edn E, Laporte JR (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165(8):869\u2013874. https:\/\/doi.org\/10.1001\/archinte.165.8.869","journal-title":"Arch Intern Med"},{"issue":"3","key":"2589_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/bf00606409","volume":"11","author":"J Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1977","unstructured":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4 J, Alhava E, Olkinuora M, Palva IP (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11(3):193\u2013198. https:\/\/doi.org\/10.1007\/bf00606409","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2589_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/17425255.2015.985649","volume":"11","author":"A Johnston","year":"2015","unstructured":"Johnston A, Uetrecht J (2015) Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol 11(2):243\u2013257. https:\/\/doi.org\/10.1517\/17425255.2015.985649","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"2589_CR22","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1021\/tx2005635","volume":"25","author":"X Li","year":"2012","unstructured":"Li X, Cameron MD (2012) Potential role of a quetiapine metabolite in quetiapine-induced neutropenia and agranulocytosis. Chem Res Toxicol 25(5):1004\u20131011. https:\/\/doi.org\/10.1021\/tx2005635","journal-title":"Chem Res Toxicol"},{"issue":"6","key":"2589_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1192\/bjp.175.6.576","volume":"175","author":"J Munro","year":"1999","unstructured":"Munro J, O\u2019Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R (1999) Active monitoring of 12760 clozapine recipients in the UK and Ireland. Br J Psychiatry 175(6):576\u2013580. https:\/\/doi.org\/10.1192\/bjp.175.6.576","journal-title":"Br J Psychiatry"},{"issue":"6","key":"2589_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4088\/JCP.12r08064","volume":"74","author":"J Nielsen","year":"2013","unstructured":"Nielsen J, Correll CU, Manu P, Kane JM (2013) Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 74(6):603\u2013613. https:\/\/doi.org\/10.4088\/JCP.12r08064. (quiz 613)","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2589_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0897190014546115","volume":"27","author":"AM Pick","year":"2014","unstructured":"Pick AM, Nystrom KK (2014) Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit? J Pharm Pract 27(5):447\u2013452. https:\/\/doi.org\/10.1177\/0897190014546115","journal-title":"J Pharm Pract"},{"key":"2589_CR26","unstructured":"Rao KV (2014) Drug-induced hematologic disorders, 24E. In: DiPiro TRJT, Yee GC et al (eds) Pharmacotherapy: a pathophysiologic approach. McGraw-Hill, 9\/E"},{"issue":"12","key":"2589_CR27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/s0895-4356(98)00072-9","volume":"51","author":"NS Rawson","year":"1998","unstructured":"Rawson NS, Harding SR, Malcolm E, Lueck L (1998) Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol 51(12):1343\u20131355. https:\/\/doi.org\/10.1016\/s0895-4356(98)00072-9","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2589_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.4269\/ajtmh.1999.60.573","volume":"60","author":"S Shapiro","year":"1999","unstructured":"Shapiro S, Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Thamprasit T, Sirijirachai J, Piankijagum A, Porapakkham Y, Vannasaeng S, Leaverton PE, Young NS (1999) Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am J Trop Med Hyg 60(4):573\u2013577. https:\/\/doi.org\/10.4269\/ajtmh.1999.60.573","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"2589_CR29","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/archinte.1992.00400190095018","volume":"152","author":"BL Strom","year":"1992","unstructured":"Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M (1992) Descriptive epidemiology of agranulocytosis. Arch Intern Med 152(7):1475\u20131480","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"2589_CR30","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1055\/s-2004-815513","volume":"37","author":"S St\u00fcbner","year":"2004","unstructured":"St\u00fcbner S, Grohmann R, Engel R, Bandelow B, Ludwig WD, Wagner G, M\u00fcller-Oerlinghausen B, M\u00f6ller HJ, Hippius H, R\u00fcther E (2004) Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 37(Suppl 1):S70-78. https:\/\/doi.org\/10.1055\/s-2004-815513","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"2589_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ajh.21433","volume":"84","author":"D Tesfa","year":"2009","unstructured":"Tesfa D, Keisu M, Palmblad J (2009) Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 84(7):428\u2013434. https:\/\/doi.org\/10.1002\/ajh.21433","journal-title":"Am J Hematol"},{"issue":"6","key":"2589_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1023\/b:ejep.0000032371.97823.85","volume":"19","author":"H Th\u00e9ophile","year":"2004","unstructured":"Th\u00e9ophile H, B\u00e9gaud B, Martin K, Laporte JR, Capella D (2004) Incidence of agranulocytosis in Southwest France. Eur J Epidemiol 19(6):563\u2013565. https:\/\/doi.org\/10.1023\/b:ejep.0000032371.97823.85","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"2589_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ajh.10295","volume":"72","author":"TP van Staa","year":"2003","unstructured":"van Staa TP, Boulton F, Cooper C, Hagenbeek A, Inskip H, Leufkens HG (2003) Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am J Hematol 72(4):248\u2013254. https:\/\/doi.org\/10.1002\/ajh.10295","journal-title":"Am J Hematol"},{"issue":"9","key":"2589_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/sim.4780120902","volume":"12","author":"SE Vollset","year":"1993","unstructured":"Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12(9):809\u2013824. https:\/\/doi.org\/10.1002\/sim.4780120902","journal-title":"Stat Med"},{"issue":"1","key":"2589_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/moh.0000000000000391","volume":"25","author":"M Wici\u0144ski","year":"2018","unstructured":"Wici\u0144ski M, W\u0119clewicz MM (2018) Clozapine-induced agranulocytosis\/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol 25(1):22\u201328. https:\/\/doi.org\/10.1097\/moh.0000000000000391","journal-title":"Curr Opin Hematol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02589-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-023-02589-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02589-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T09:05:59Z","timestamp":1675674359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-023-02589-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1007\/s00702-023-02589-7","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"24 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Bleich, S. St\u00fcbner, T. Held, G. Burkhardt and C. Glocker have no competing interests to declare that are relevant to the content of this article. C. Sch\u00fcle has been a member of the advisory board of Janssen-Cilag and has received speaker\u00b4s honoraria from Janssen-Cilag, Lundbeck, Bristol-Myers Squibb, and Neuraxpharm. S. Toto, and R. Grohmann are project managers of the AMSP program; S. Toto is a member of the advisory board for Otsuka and Janssen-Cilag and has received speaker\u00b4s honoraria from Janssen-Cilag, Lundbeck\/Otsuka, Recordati Pharma GmbH, and Servier.J. Seifert has taken part in educational events sponsored by Otsuka\/Lundbeck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}